![Mayer Geert](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Mayer Geert
Corporate Officer/Principal chez University of Göttingen
Provenance du réseau au premier degré de Mayer Geert
Entité | Type d'entité | Industrie | |
---|---|---|---|
University of Göttingen
2
| College/University | Other Consumer Services | 2 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Mayer Geert via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
Cell Medica Switzerland AG
![]() Cell Medica Switzerland AG Pharmaceuticals: MajorHealth Technology Cell Medica Switzerland AG engages in the research, development, production, and distribution of pharmaceutical, biological, medical, and diagnostic products. It provides locally and systemically applied antibody therapeutics under the PENTRA Body platform. The company was founded by Thomas O. Hecht on September 4, 2009 and is headquartered in Schlieren, Switzerland. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Novartis Institutes for Biomedical Research, Inc.
![]() Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
NOVARTIS AG | Pharmaceuticals: Major | Corporate Officer/Principal | |
AIMM Therapeutics BV
![]() AIMM Therapeutics BV Pharmaceuticals: MajorHealth Technology AIMM Therapeutics BV develops therapeutic antibodies for the treatment of cancer and infectious diseases. Its antibody discovery platform couples proprietary knowledge of B cell immortalization with the isolation of antibodies from humans or animals. The company was founded by Donald Kalff and Hergen Spits in 2004 and is headquartered in Amsterdam, the Netherlands. | Pharmaceuticals: Major | Director/Board Member | |
Philipps University of Marburg | College/University | Doctorate Degree | |
Actieninvest AG
![]() Actieninvest AG Investment ManagersFinance Actieninvest AG is a Swiss independent asset management company for private investors that provides wealth management services committed to clients' interests. The company is based in Zurich, Switzerland, and has subsidiaries in Switzerland. The company offers personal support and has extensive experience in the holistic management of fixed assets, ensuring a long-term relationship with clients. Actieninvest maintains excellent relationships with renowned Swiss banking institutions, offering clients permanently advantageous conditions for their personal investment. The company implements the jointly developed investment policy based on a limited administrative power of attorney, and the fee structure is simple and transparent. Actieninvest also provides holistic support to families, including the structuring and support of assets, administrative, accounting, and other supporting functions. The company was founded in 1987, and Claudio Pedrett has been the CEO of the company since 2001. | Investment Managers | Portfolio Manager-Equities | |
Macquarie University | College/University | Doctorate Degree |
Statistiques
Internationale
Suisse | 5 |
Etats-Unis | 2 |
Pays-Bas | 2 |
Allemagne | 2 |
Australie | 2 |
Sectorielle
Health Technology | 5 |
Consumer Services | 3 |
Commercial Services | 2 |
Finance | 2 |
Opérationnelle
Corporate Officer/Principal | 4 |
Doctorate Degree | 2 |
Chief Tech/Sci/R&D Officer | 1 |
Director/Board Member | 1 |
Portfolio Manager-Equities | 1 |
Relations les plus connectées
Insiders | |
---|---|
Thomas Jung | 7 |
Marcel Rothenberger | 3 |
- Bourse
- Insiders
- Mayer Geert
- Connexions Sociétés